Literature DB >> 12639988

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Christopher T Ritchlin1, Sally A Haas-Smith, Ping Li, David G Hicks, Edward M Schwarz.   

Abstract

Psoriatic arthritis (PsA) is an inflammatory joint disease characterized by extensive bone resorption. The mechanisms underlying this matrix loss have not been elucidated. We report here that blood samples from PsA patients, particularly those with bone erosions visible on plain radiographs, exhibit a marked increase in osteoclast precursors (OCPs) compared with those from healthy controls. Moreover, PsA PBMCs readily formed osteoclasts in vitro without exogenous receptor activator of NF-kappaB ligand (RANKL) or MCSF. Both osteoprotegerin (OPG) and anti-TNF antibodies inhibited osteoclast formation. Additionally, cultured PsA PBMCs spontaneously secreted higher levels of TNF-alpha than did healthy controls. In vivo, OCP frequency declined substantially in PsA patients following treatment with anti-TNF agents. Immunohistochemical analysis of subchondral bone and synovium revealed RANK-positive perivascular mononuclear cells and osteoclasts in PsA specimens. RANKL expression was dramatically upregulated in the synovial lining layer, while OPG immunostaining was restricted to the endothelium. These results suggest a model for understanding the pathogenesis of aggressive bone erosions in PsA. OCPs arise from TNF-alpha-activated PBMCs that migrate to the inflamed synovium and subchondral bone, where they are exposed to unopposed RANKL and TNF-alpha. This leads to osteoclastogenesis at the erosion front and in subchondral bone, resulting in a bidirectional assault on psoriatic bone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639988      PMCID: PMC153764          DOI: 10.1172/JCI16069

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Cytokine-activated endothelium recruits osteoclast precursors.

Authors:  N W McGowan; E J Walker; H Macpherson; S H Ralston; M H Helfrich
Journal:  Endocrinology       Date:  2001-04       Impact factor: 4.736

Review 2.  The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis.

Authors:  L C Hofbauer; A E Heufelder
Journal:  Arthritis Rheum       Date:  2001-02

3.  Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis.

Authors:  P Collin-Osdoby; L Rothe; F Anderson; M Nelson; W Maloney; P Osdoby
Journal:  J Biol Chem       Date:  2001-03-23       Impact factor: 5.157

4.  Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.

Authors:  S Kotake; N Udagawa; M Hakoda; M Mogi; K Yano; E Tsuda; K Takahashi; T Furuya; S Ishiyama; K J Kim; S Saito; T Nishikawa; N Takahashi; A Togari; T Tomatsu; T Suda; N Kamatani
Journal:  Arthritis Rheum       Date:  2001-05

5.  Expression of interleukin 10 mRNA and protein by synovial fibroblastoid cells.

Authors:  C Ritchlin; S A Haas-Smith
Journal:  J Rheumatol       Date:  2001-04       Impact factor: 4.666

6.  The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.

Authors:  F Gori; L C Hofbauer; C R Dunstan; T C Spelsberg; S Khosla; B L Riggs
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

7.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

Authors:  H Takayanagi; K Ogasawara; S Hida; T Chiba; S Murata; K Sato; A Takaoka; T Yokochi; H Oda; K Tanaka; K Nakamura; T Taniguchi
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

8.  Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL).

Authors:  G C Nicholson; M Malakellis; F M Collier; P U Cameron; W R Holloway; T J Gough; C Gregorio-King; M A Kirkland; D E Myers
Journal:  Clin Sci (Lond)       Date:  2000-08       Impact factor: 6.124

9.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.

Authors:  J Lam; S Takeshita; J E Barker; O Kanagawa; F P Ross; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 10.  Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications.

Authors:  S R Goldring; E M Gravallese
Journal:  Arthritis Res       Date:  1999-12-22
View more
  177 in total

1.  Role of TNF alpha and PLF in bone remodeling in a rat model of repetitive reaching and grasping.

Authors:  Shobha Rani; Mary F Barbe; Ann E Barr; Judith Litivn
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

2.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

3.  Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion.

Authors:  R E Kast; E L Altschuler
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 4.  Secukinumab: a promising therapeutic option in spondyloarthritis.

Authors:  Hernan Maldonado-Ficco; Rodolfo Perez-Alamino; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2016-07-20       Impact factor: 2.980

5.  Myeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts.

Authors:  Hui Zhang; Yuefang Huang; Shuang Wang; Rong Fu; Chaohuan Guo; Hongyue Wang; Jijun Zhao; Felicia Gaskin; Jingxian Chen; Niansheng Yang; Shu Man Fu
Journal:  J Autoimmun       Date:  2015-08-28       Impact factor: 7.094

Review 6.  Mechanisms of pathologic new bone formation.

Authors:  Kurt de Vlam; Rik J U Lories; Frank P Luyten
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

7.  Bone mineral density and bone turnover in patients with psoriatic arthritis.

Authors:  Pinar Borman; Seçil Babaoğlu; Guneş Gur; Sezin Bingol; Hatice Bodur
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

Review 8.  Altered bone remodeling in psoriatic arthritis.

Authors:  Kofi A Mensah; Edward M Schwarz; Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

Review 9.  MRI in psoriatic arthritis: insights into pathogenesis and treatment response.

Authors:  Fiona M McQueen; Nicola Dalbeth; Anthony Doyle
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

10.  Lipopolysaccharide-induced epithelial monoamine oxidase mediates alveolar bone loss in a rat chronic wound model.

Authors:  Daisuke Ekuni; James D Firth; Tarun Nayer; Takaaki Tomofuji; Toshihiro Sanbe; Koichiro Irie; Tatsuo Yamamoto; Takashi Oka; Zhenzi Liu; Juergen Vielkind; Edward E Putnins
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.